Skip to content

Orsiro Mission 2.5/35/140Recalls & reported problems

Biotronik AG · Class 3 · Implant

All models of Orsiro Mission (49)

Data updated Oct 18, 2026 from official FDA records · Editorial policy

Adverse event reports
8
Deaths reported
0
Injuries reported
0
Recalls naming it
0

Summary

The FDA's MAUDE database contains 8 adverse event reports that list this exact device (DI 07640130456242), received between Feb 6, 2024 and Apr 28, 2026 — classified as 8 malfunctions.

The most frequently reported specific device problem is “Failure to Advance” (6 reports).

Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event, and counts can't be used to compare devices or estimate failure rates. What reports can and can't tell you · How this data works · Data updated Oct 18, 2026.

Reports received per month

Nov 2023: 0 reportsDec 2023: 0 reportsJan 2024: 0 reportsFeb 2024: 1 reportsMar 2024: 0 reportsApr 2024: 0 reportsMay 2024: 1 reportsJun 2024: 0 reportsJul 2024: 0 reportsAug 2024: 0 reportsSep 2024: 0 reportsOct 2024: 0 reportsNov 2024: 0 reportsDec 2024: 0 reportsJan 2025: 0 reportsFeb 2025: 0 reportsMar 2025: 0 reportsApr 2025: 0 reportsMay 2025: 0 reportsJun 2025: 0 reportsJul 2025: 1 reportsAug 2025: 0 reportsSep 2025: 0 reportsOct 2025: 0 reportsNov 2025: 0 reportsDec 2025: 2 reportsJan 2026: 1 reportsFeb 2026: 1 reportsMar 2026: 0 reportsApr 2026: 1 reportsMay 2026: 0 reportsJun 2026: 0 reportsJul 2026: 0 reportsAug 2026: 0 reportsSep 2026: 0 reportsOct 2026: 0 reports2024202520262
Last 36 months. The most recent month may be incomplete.

Most reported problems

Device problems

  • Failure to Advance6
  • Material Deformation2
  • Device Dislodged or Dislocated1

Patient problems

  • No Clinical Signs, Symptoms or Conditions8

Recent adverse event reports

The 8 most recent of 8 reports, in the reporter's own words as published by the FDA.

  • MalfunctionApr 28, 2026Failure to Advance

    THE ORSIRO MISSION DRUG-ELUTING STENT SYSTEM WAS SELECTED FOR TREATMENT OF A MODERATELY CALCIFIED LESION (99 % STENOSIS DEGREE) IN A SEVERELY TORTUOUS SEGMENT OF THE DISTAL RCA. A PRE-DILATION OF THE LESION WAS PER-FORMED. THE AFFECTED DEVICE WAS INTRODUCED INTO THE PATIENT'S BODY BUT COULD NOT CROSS THE LESION "DUE TO THE SEVERE TORTUOSITY OF THE VESSEL".

    Patient problems: No Clinical Signs, Symptoms or Conditions

    MAUDE report 25013114 ↗
  • MalfunctionFeb 13, 2026Failure to Advance

    THE ORSIRO MISSION DRUG-ELUTING STENT SYSTEM WAS SELECTED FOR TREATMENT OF A MODERATELY CALCIFIED LESION IN A MODERATELY TORTUOUS SEGMENT OF THE PROXIMAL LCX. A PRE-DILATION OF THE LESION WAS PERFORMED. THE AFFECTED DEVICE WAS INTRODUCED INTO THE PATIENT'S BODY BUT COULD NOT CROSS THE LESION.

    Patient problems: No Clinical Signs, Symptoms or Conditions

    MAUDE report 24332224 ↗
  • MalfunctionJan 7, 2026Failure to Advance

    THE ORSIRO MISSION DRUG-ELUTING STENT SYSTEM WAS SELECTED FOR TREATMENT OF A LESION WITH 60% STENOSIS DEGREE. IT IS UNKNOWN IF A PRE-DILATION OF THE LESION WAS PERFORMED. THE AFFECTED DEVICE WAS INTRODUCED INTO THE PATIENT'S BODY BUT COULD NOT CROSS THE LESION. THE COMPLAINT DEVICE WAS DISCARDED AT THE HOSPITAL.

    Patient problems: No Clinical Signs, Symptoms or Conditions

    MAUDE report 23988606 ↗
  • MalfunctionDec 10, 2025Failure to Advance; Failure to Advance

    THE ORSIRO MISSION DRUG-ELUTING STENT SYSTEM WAS SELECTED FOR TREATMENT OF A SEVERELY CALCIFIED LESION IN A SEVERELY TORTUOUS PART OF THE MID LAD. DESPITE PRE-DILATATION AND SEVERAL ATTEMPTS, THE DEVICE COULD NOT PASS THE LESION. ADDITIONAL BALLOON DILATATION WAS PERFORMED AND ANOTHER ORSIRO MISSION WAS INSERTED.

    Patient problems: No Clinical Signs, Symptoms or Conditions

    MAUDE report 23766960 ↗
  • MalfunctionDec 3, 2025Failure to Advance; Failure to Advance

    THE ORSIRO MISSION DRUG-ELUTING STENT SYSTEM WAS SELECTED FOR TREATMENT OF A MODERATELY CALCIFIED LESION IN A MODERATELY TORTUOUS PART OF THE MID RCA. THE DEVICE COULD NOT CROSS THE LESION.

    Patient problems: No Clinical Signs, Symptoms or Conditions

    MAUDE report 23703544 ↗
  • MalfunctionJul 2, 2025Device Dislodged or Dislocated; Device Dislodged or Dislocated

    THE ORSIRO MISSION STENT WAS UNABLE TO CROSS THE SEVERELY CALCIFIED LESION IN THE LAD. WHEN THE DEVICE WAS REMOVED, IT WAS DISCOVERED THAT THE STENT WAS NO LONGER ON THE DELIVERY SYSTEM. THE STENT WAS FOUND AND LEFT IN THE LEFT ILIAC ARTERY. NO FURTHER TREATMENT WAS CONDUCTED.

    Patient problems: No Clinical Signs, Symptoms or Conditions

    MAUDE report 22381661 ↗
  • MalfunctionMay 29, 2024Material Deformation; Material Deformation

    AN ORSIRO MISSION DRUG-ELUTING STENT SYSTEM WAS SELECTED FOR TREATMENT. DURING UNPACKING, THE STENT LOOKED WARPED COMING OUT OF THE HOOP.

    Patient problems: No Clinical Signs, Symptoms or Conditions

    MAUDE report 19415268 ↗
  • MalfunctionFeb 6, 2024Failure to Advance; Material Deformation; Failure to Advance; Material Deformation

    AN ORSIRO MISSION DRUG-ELUTING STENT SYSTEM WAS SELECTED FOR TREATMENT OF A MODERATELY CALCIFIED LESION IN THE SEVERELY TORTUOUS DISTAL LCX. DESPITE PRE DILATATION, THE LESION COULD NOT BE CROSSED WITH THE DEVICE. THE LESION WAS RE DILATED WITH A LARGER NC BALLOON. UPON INSPECTION AND BEFORE RE-INSERTING THE STENT, THE PROXIMAL END OF THE STENT WAS OBSERVED TO BE DAMAGED. THERE WAS NO RESISTANCE IN REMOVING THE STENT INITIALLY FROM THE BODY. IT IS NOT CERTAIN WHAT CAUSED THE DAMAGE.

    Patient problems: No Clinical Signs, Symptoms or Conditions

    MAUDE report 18649608 ↗

Other Coronary drug-eluting stent devices

All Coronary drug-eluting stent devices →

Sources and updates

How reports and recalls are matched · Editorial policy · Report an error on this page